Amgen’s dazodalibep meets primary endpoint in Sjögren’s trial
Amgen (AMGN) reported that its Phase 3 trial of dazodalibep met the primary endpoint in treating Sjögren’s disease, showing significant improvement at Week 48. The study enrolled 621 patients. Dazodalibep is not yet FDA-approved. Amgen plans to share detailed data at a future medical meeting. The company's Phase 3 OASIZ 303 study is expected to complete in Q4 2026.
How this was made
The 30-second read
Why it matters
The data represent a material clinical milestone that could expand Amgen's product portfolio.
Market read
First‑time positive Phase 3 data for an unmet autoimmune disease, likely to influence Amgen's stock and sector sentiment.
What to watch
Potential safety signals in longer‑term data and competition from emerging biologics.
Background
Amgen announced the trial results via press release; no prior public disclosure existed.
Ticker impact
Amgen's Phase 3 dazodalibep trial met its primary endpoint in Sjögren's disease.
Potential upside of 5‑10% over the next week as investors price in a new indication.
First‑time disclosure of statistically significant efficacy in an unmet‑need autoimmune disease, with no approved therapies.
Market effects
May lift sentiment for biotech firms developing autoimmune therapies.
Positive for US biotech sector; limited global spillover.
Highlights growing pipeline potential in rare disease space.
Counterpoint
Skeptics may question commercial viability and reimbursement risk for a niche indication.
Key entities
- CompanyAmgen
US‑listed biotech developing dazodalibep.
